secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-044934
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share
--------------------------------------------------------------------------------

- Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.
- Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.
- Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.
- Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.
- Offering made under existing shelf registration statement; customary underwriting agreement terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/0001193125-26-044934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/d52363d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-044934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer